Log in
NASDAQ:CSBR

Champions Oncology Stock Forecast, Price & News

$9.11
+0.50 (+5.81 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$8.42
Now: $9.11
$9.11
50-Day Range
$7.05
MA: $8.54
$9.97
52-Week Range
$4.02
Now: $9.11
$10.89
Volume40,904 shs
Average Volume38,115 shs
Market Capitalization$115.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.21
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The company also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and provides access to gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying potentially useful drugs. In addition, it offers Translational Oncology Solutions, including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies. Champions Oncology, Inc. markets its products through Internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Read More
Champions Oncology logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.72 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CSBR
CUSIPN/A
Phone201-808-8400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.12 million
Book Value$0.45 per share

Profitability

Net Income$-1,980,000.00

Miscellaneous

Employees92
Market Cap$115.95 million
Next Earnings Date12/21/2020 (Estimated)
OptionableNot Optionable
$9.11
+0.50 (+5.81 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CSBR News and Ratings via Email

Sign-up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Champions Oncology (NASDAQ:CSBR) Frequently Asked Questions

How has Champions Oncology's stock price been impacted by Coronavirus?

Champions Oncology's stock was trading at $4.97 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CSBR shares have increased by 83.3% and is now trading at $9.11.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Champions Oncology?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Champions Oncology
.

When is Champions Oncology's next earnings date?

Champions Oncology is scheduled to release its next quarterly earnings announcement on Monday, December 21st 2020.
View our earnings forecast for Champions Oncology
.

How were Champions Oncology's earnings last quarter?

Champions Oncology Inc (NASDAQ:CSBR) posted its earnings results on Monday, September, 14th. The biotechnology company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.02 by $0.01. Champions Oncology had a negative return on equity of 35.57% and a negative net margin of 3.60%.
View Champions Oncology's earnings history
.

What price target have analysts set for CSBR?

2 brokerages have issued 1 year target prices for Champions Oncology's shares. Their forecasts range from $9.25 to $11.00. On average, they anticipate Champions Oncology's stock price to reach $10.13 in the next twelve months. This suggests a possible upside of 11.1% from the stock's current price.
View analysts' price targets for Champions Oncology
.

Who are some of Champions Oncology's key competitors?

What other stocks do shareholders of Champions Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Champions Oncology investors own include Gilead Sciences (GILD), Intel (INTC), Cytosorbents (CTSO), Micron Technology (MU), Corbus Pharmaceuticals (CRBP), NVIDIA (NVDA), AbbVie (ABBV), Crispr Therapeutics (CRSP), Exelixis (EXEL) and Pfizer (PFE).

Who are Champions Oncology's key executives?

Champions Oncology's management team includes the following people:
  • Dr. Ronnie Morris, CEO & Director (Age 53)
  • Mr. David Barry Miller, Chief Financial Officer (Age 50)
  • Dr. Philip P. Breitfeld, Chief Strategy & Innovation Officer and Director (Age 66)
  • Mr. Mark Weinstein, Chief Information Officer
  • Mr. Bruce Ruggeri, Chief Scientific Officer

What is Champions Oncology's stock symbol?

Champions Oncology trades on the NASDAQ under the ticker symbol "CSBR."

Who are Champions Oncology's major shareholders?

Champions Oncology's stock is owned by many different institutional and retail investors. Top institutional investors include Cadence Capital Management LLC (1.83%), Bank of Montreal Can (0.81%), Bank of New York Mellon Corp (0.55%), ClariVest Asset Management LLC (0.45%), Cowen Prime Services LLC (0.46%) and Globeflex Capital L P (0.29%). Company insiders that own Champions Oncology stock include Daniel Newman Mendelson, Enterprise Associates 14 New, Joel Ackerman and Ronnie Morris.
View institutional ownership trends for Champions Oncology
.

Which major investors are selling Champions Oncology stock?

CSBR stock was sold by a variety of institutional investors in the last quarter, including Cowen Prime Services LLC, Ingalls & Snyder LLC, and ClariVest Asset Management LLC. Company insiders that have sold Champions Oncology company stock in the last year include Enterprise Associates 14 New, and Ronnie Morris.
View insider buying and selling activity for Champions Oncology
.

Which major investors are buying Champions Oncology stock?

CSBR stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., Globeflex Capital L P, Nuveen Asset Management LLC, New York State Common Retirement Fund, Cadence Capital Management LLC, Bank of America Corp DE, and Bank of Montreal Can. Company insiders that have bought Champions Oncology stock in the last two years include Daniel Newman Mendelson, and Ronnie Morris.
View insider buying and selling activity for Champions Oncology
.

How do I buy shares of Champions Oncology?

Shares of CSBR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Champions Oncology's stock price today?

One share of CSBR stock can currently be purchased for approximately $9.11.

How big of a company is Champions Oncology?

Champions Oncology has a market capitalization of $115.95 million and generates $32.12 million in revenue each year. The biotechnology company earns $-1,980,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Champions Oncology employs 92 workers across the globe.

What is Champions Oncology's official website?

The official website for Champions Oncology is www.championsoncology.com.

How can I contact Champions Oncology?

Champions Oncology's mailing address is One University Plaza Suite 307, Hackensack NJ, 07601. The biotechnology company can be reached via phone at 201-808-8400 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.